Phase I trial of intratumoral pIL-12 [gene therapy] electroporation in malignant melanoma

Trial Profile

Phase I trial of intratumoral pIL-12 [gene therapy] electroporation in malignant melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Tavokinogene telsaplasmid (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 Apr 2016 Results of retrospective analysis of long-term, follow-up data published in an OncoSec media release.
    • 19 Apr 2016 Results of retrospective analysis of long-term, follow-up data were presented at the the American Association of Cancer Research (AACR) Annual Meeting 2016, according to an OncoSec Medical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top